Protara Therapeutics, Inc. (TARA)
3.82
-0.17
(-4.26%)
USD |
NASDAQ |
Aug 28, 16:00
3.815
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Cash from Operations (Quarterly) : -15.39M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.39M |
| March 31, 2026 | -21.34M |
| December 31, 2025 | -16.95M |
| September 30, 2025 | -12.45M |
| June 30, 2025 | -12.25M |
| March 31, 2025 | -14.71M |
| December 31, 2024 | -9.308M |
| September 30, 2024 | -8.434M |
| June 30, 2024 | -7.687M |
| March 31, 2024 | -10.38M |
| December 31, 2023 | -8.70M |
| September 30, 2023 | -6.561M |
| June 30, 2023 | -9.408M |
| March 31, 2023 | -12.89M |
| December 31, 2022 | -5.026M |
| September 30, 2022 | -5.347M |
| June 30, 2022 | -5.123M |
| March 31, 2022 | -10.96M |
| December 31, 2021 | -6.907M |
| September 30, 2021 | -6.201M |
| June 30, 2021 | -9.474M |
| March 31, 2021 | -11.92M |
| December 31, 2020 | -6.766M |
| September 30, 2020 | -3.762M |
| June 30, 2020 | -5.733M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.146M |
| December 31, 2019 | -1.089M |
| September 30, 2019 | -1.213M |
| June 30, 2019 | -1.304M |
| March 31, 2019 | -1.406M |
| December 31, 2018 | -4.313M |
| September 30, 2018 | -3.116M |
| June 30, 2018 | -10.35M |
| March 31, 2018 | -5.456M |
| December 31, 2017 | -5.698M |
| September 30, 2017 | -5.926M |
| June 30, 2017 | -3.282M |
| March 31, 2017 | -7.446M |
| December 31, 2016 | -5.579M |
| September 30, 2016 | -6.646M |
| June 30, 2016 | -5.568M |
| March 31, 2016 | -5.894M |
| December 31, 2015 | -5.186M |
| September 30, 2015 | -3.91M |
| June 30, 2015 | -4.597M |
| March 31, 2015 | -3.873M |
| December 31, 2014 | -2.05M |
| September 30, 2014 | -3.706M |
| June 30, 2014 | -2.672M |
| March 31, 2014 | -1.562M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0336M |
| Brainstorm Cell Therapeutics, Inc. | -0.895M |
| Summit Therapeutics, Inc. | -140.55M |
| Kezar Life Sciences, Inc. | -7.445M |
| Clene, Inc. | -2.578M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 17.75M |
| Cash from Financing (Quarterly) | -0.026M |
| Free Cash Flow | -66.49M |
| Free Cash Flow Per Share (Quarterly) | -0.2577 |
| Free Cash Flow to Equity (Quarterly) | -15.41M |
| Free Cash Flow to Firm (Quarterly) | -15.72M |
| Free Cash Flow Yield | -33.66% |